Medivir's (MVIRB SS) nucleotide project could attract takeover interest for the company -
Medivir, the Swedish pharmaceutical company, could be a candidate for takeover, according to Dagens Industri. The Swedish business daily speculated that the American pharma giant Merck’s USD 3.5bn offer for Idenix this week could increase the chance of a Medivir takeover.
The paper reported that Merck’s interest in Idenix is based on Idenix’s nucleotide drugs against hepatitis C. The item noted that there is a lack of nucleotide projects but that Medivir has an ongoing preclinical phase nucleotide project which could attract takeover interest. The paper pointed out that one potential bidder could be Medivir’s American Simpeprevir partner, Johnson & Johnson.
Source Dagens Industri